daraxonrasib
daraxonrasib: developed by 1 company · 17 clinical trials tracked.
daraxonrasib evidence translation
What we can confirm
17 tracked trials
What it means
What to watch
Prepared research question
How could daraxonrasib → RVMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| REVOLUTION MEDICINES, INC. (RVMD) Non-small Cell Lung Cancer (NSCLC); PDAC; NSCLC (Non-small C… | Phase 3 |
Clinical Trials (17)showing 10 most recent
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Primary endpoint: Objective Response (ORR)
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Primary endpoint: Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Part 1: Number of participants who achieve Objective Response (OR)
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Primary endpoint: Disease-Free Survival (DFS) per Investigator
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
Primary endpoint: Phase 1: Maximum Tolerated Dose
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
Frequently asked questions
Who is developing daraxonrasib?
daraxonrasib is being developed by REVOLUTION MEDICINES, INC..
How many clinical trials involve daraxonrasib?
BioSniper tracks 17 clinical trials involving daraxonrasib.